Overview
Medical degree at the University of Buenos Aires. Residency/Cardiology Fellowship at the Sanatorio Guemes/Favaloro Foundation. Cardiac cath fellow at the Sanatorio Guemes. International Scholar in Artificial Organs at the Cleveland Clinic. Duke Clinical Research Institute research fellow.
Faculty member in the Cardiology Division at the University of Texas Medical Branch with the rank of Assoc Professor of Medicine as CCU and Cardiac Cath Lab attending (invasive cardiologist) on all type of cardiovascular diseases Director or Associated Dir of the Advanced Heart Failure that included devices such as aquapheresis, 2.5 impella, Cardiac Power, and surgical such as being part of the approval team for destination therapy on Heart Mate II. UNOS primary physician in the Heart Transplant program 2011-2013. Current Adj Ast Professor Medicine/Cardiology at Duke University, member of the Board of Directors of DUCCS (a Duke Clinical Research organization). Director of the Advanced Heart Failure Postgraduate Program at the Universidad Catolica Argentina (UCA). Staff member Interventional Cardiology service at the Instituto del diagnostico y tratamiento, Buenos Aires, Argentina.
Research Interest in Acute Myocardial Infarction and Heart Failure, percutaneous and surgical devices in heart failure. Early identification of STEMI such as criteria's for MI in LBBB (http://en.wikipedia.org/wiki/Sgarbossa's_criteria), new descriptors in Q wave/non Q wave, use of telemedicine for timeliness reperfusion. Co-editor of the book on “prehospital Management of Acute Myocardial Infarction” Member of the Int. Speaker Bureau AHA. Published more than 60 peer articles and more than 100 hundred abstract and speaker in a number of Scientific Meetings.
Faculty member in the Cardiology Division at the University of Texas Medical Branch with the rank of Assoc Professor of Medicine as CCU and Cardiac Cath Lab attending (invasive cardiologist) on all type of cardiovascular diseases Director or Associated Dir of the Advanced Heart Failure that included devices such as aquapheresis, 2.5 impella, Cardiac Power, and surgical such as being part of the approval team for destination therapy on Heart Mate II. UNOS primary physician in the Heart Transplant program 2011-2013. Current Adj Ast Professor Medicine/Cardiology at Duke University, member of the Board of Directors of DUCCS (a Duke Clinical Research organization). Director of the Advanced Heart Failure Postgraduate Program at the Universidad Catolica Argentina (UCA). Staff member Interventional Cardiology service at the Instituto del diagnostico y tratamiento, Buenos Aires, Argentina.
Research Interest in Acute Myocardial Infarction and Heart Failure, percutaneous and surgical devices in heart failure. Early identification of STEMI such as criteria's for MI in LBBB (http://en.wikipedia.org/wiki/Sgarbossa's_criteria), new descriptors in Q wave/non Q wave, use of telemedicine for timeliness reperfusion. Co-editor of the book on “prehospital Management of Acute Myocardial Infarction” Member of the Int. Speaker Bureau AHA. Published more than 60 peer articles and more than 100 hundred abstract and speaker in a number of Scientific Meetings.
Current Duke Appointments & Affiliations
Adjunct Professor in the Department of Medicine
·
2016 - Present
Medicine, Cardiology,
Medicine
Recent Scholarly Works
Device-based therapies for cardiorenal syndrome: A comprehensive, mechanism-driven framework for next-generation decongestion.
Journal article Eur J Intern Med · September 2026 BACKGROUND: Cardiorenal dysfunction is a major contributor to morbidity, rehospitalization, and mortality in advanced heart failure (HF) and cardiogenic shock. Traditional decongestive approaches-loop diuretics, combination natriuretics, and ultrafiltratio ... Full text Link to item CiteClinical Consequences of Withdrawing Guideline-Directed Medical Therapy in Heart Failure with Improved Ejection Fraction: A Systematic Review and Meta-Analysis.
Journal article Crit Pathw Cardiol · July 22, 2026 Heart failure with reduced ejection fraction (HFrEF) and heart failure with improved ejection fraction (HFimpEF) represent dynamic states modifiable by pharmacologic therapy. Guideline Directed Medical Therapy (GDMT) reduces morbidity and mortality in HFrE ... Full text Link to item CiteValve-Specific Comparative Effectiveness of Direct Oral Anticoagulants Versus Vitamin K Antagonists After Surgical Valve Procedures in Atrial Fibrillation: A Systematic Review and Meta-Analysis.
Journal article Cardiol Rev · July 2, 2026 Anticoagulation after left-sided bioprosthetic valve replacement or mitral valve repair in patients with atrial fibrillation (AF) remains uncertain, as decisions must balance prevention of thromboembolism against bleeding risk in a heterogeneous postoperat ... Full text Link to item CiteEducation
University of Buenos Aires (Argentina) ·
1982
M.D.